[Action mechanisms of Xiaoluowan (II) in the treatment of epididymitis: A network pharmacology-based study].
Zhonghua Nan Ke Xue
; 29(4): 298-305, 2023 Apr.
Article
en Zh
| MEDLINE
| ID: mdl-38598212
ABSTRACT
OBJECTIVE:
To explore the potential action mechanisms of Xiaoluowan (II) (XLW-II) in the treatment of epididymitis through a network pharmacology approach.METHODS:
We searched various databases for relevant targets associated with epididymitis and XLW-II and obtained the common targets of epididymitis and XLW-II on the Venny platform. We acquired the protein-protein interactions (PPI) using the STRING data and had them visualized with the Cytoscape software. After topological analysis, we retrieved the key targets, followed by gene ontology (GO) and KEGG pathway enrichment analyses using the DAVID database.RESULTS:
A total of 2 38 drug targets, 2 150 disease targets and 85 common targets were identified. The core targets for the treatment of epididymitis with XLW-II identified by PPI network analysis included TNF, IL6, IL1B, MMP9, AKT1, PTGS2 and TP53. GO function analysis revealed the involvement of the common targets in such biological processes as response to hypoxia, regulation of apoptotic processes, inflammatory response, and positive regulation of the MAPK cascade. KEGG pathway analysis suggested that the signaling pathways such as the cancer pathway, PI3K-Akt pathway, protein glycosylation pathway in cancer, Ras pathway and chemokine pathway might be related to the action mechanisms of XLW-II in the treatment of epididymitis.CONCLUSION:
The potential targets and signaling pathways of Xiaoluowan (II) in the treatment of epididymitis were identified on the basis of network pharmacology, which has provided a novel insight into its action mechanisms and offered a new direction for further relevant studies.Palabras clave
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Medicamentos Herbarios Chinos
/
Epididimitis
/
Neoplasias
Idioma:
Zh
Revista:
Zhonghua Nan Ke Xue
Año:
2023
Tipo del documento:
Article
País de afiliación:
China